Clinical Trial Update: Immunologic Determinants of Response to Pembrolizumab (MK-3475) in Advanced Melanoma (MK-3475-161/KEYNOTE-161) [Phase 2]

View source ↗

Summary

Phase 2 trial investigating immunologic determinants of response to pembrolizumab (MK-3475) in advanced melanoma; study terminated with posted results in 2020.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Melanoma

Drugs mentioned

• Pembrolizumab (pembrolizumab)

Snippet

Sponsor: Merck Sharp & Dohme LLC | Conditions: Advanced Melanoma | Phase 2 | Status: TERMINATED | Results posted: 2020-07-15